December 21, 2023

Execution of Share Transfer Agreement on Overseas Joint Venture Subsidiary
Mitsubishi Tanabe Pharma Corporation (Headquarters: Chuo-ku, Osaka; Representative
Director: Akihiro Tsujimura; hereinafter, "MTPC"), a member of Mitsubishi Chemical Group,announced that MTPC has recently executed share purchase/transfer agreement with Grand
Pharma (China) Co., Ltd. (Head Office: Wuhan, Hubei Province, China; Representative
President: Weikun Tang; hereinafter, “Grand Pharma (China)”) to transfer its share and interestin Tianjin Tanabe Seiyaku Co., Ltd. (Head Office: Tianjin, China; Chairman: Ping Zhang;hereinafter, "Tianjin Tanabe"), an overseas consolidated subsidiary of MTPC. Tianjin Lisheng
Pharmaceutical Co., Ltd. (Head Office: Tianjin, China; Chairman: Ping Zhang; hereinafter,"Tianjin Lisheng"), which jointly owns shares in Tianjin Tanabe, has waived its right topreferentially purchase MTPC’s share in Tianjin Tanabe.
Background to execution of share transfer agreement
Since its establishment in 1993, Tianjin Tanabe has contributed to patients in China throughthe manufacturing and marketing of high-quality pharmaceutical products for cardiovasculardiseases, gastrointestinal diseases and antiallergic diseases. However, considering the recentchanges in the business environment in China, MTPC has decided to transfer its share in Tianjin
Tanabe to a company with deep knowledge of the Chinese market to lead the further growthand competitiveness of Tianjin Tanabe.
Grand Pharma (China) is a core company of Grand Pharmaceutical Group Limited. Grand
Pharma (China) is a pharmaceutical company with strengths in the manufacture and marketingof cardiovascular medicines, etc. and has positioned expansion of its cardiovascular productlineup and improvement of production and supply capacity as one of its business strategies.
MTPC firmly believes that Tianjin Tanabe will be able to develop and grow its business withtaking advantage of its strengths by becoming a subsidiary of Grand Pharma (China).
1.

2.




3.







Outline of Tianjin Tanabe
Corporate name: Tianjin Tanabe Seiyaku Co., Ltd.
Location: No. 16 MIP Third Road, Micro-Electronics Industrial Park, Tianjin EconomicTechnological Development Area, Tianjin, China
Representatives: Chairman Ping Zhang, President Kazuyuki Shioya
Registered Capital: US $16.23 million
Sales: 402,696,000 RMB (as of 2022)
Business activities: Manufacturing and marketing of pharmaceutical products
Number of employees: 384 (as of the end of November 2023)
Equity holders: MTPC 75.35%, Tianjin Lisheng 24.65%
Outline of the party to which share transfer agreement has executed
Corporate name: Grand Pharma (China) Co., Ltd.
Location: No. 1-6, 23F, Building 1, No. 160 Qiaokou Road, Qiaokou District, Wuhan City,Hubei Province, China
Representative President: Weikun Tang
Registered capital: 4,906,230,000 RMB
Sales: Not disclosed
Business activities: Manufacturing and marketing of pharmaceutical products
Number of employees: Not disclosed
Equity holders: Grand Pharmaceutical Group Limited 99.84%

4. Share transfer value
7,364 million Japanese Yen

1/2

5. Impact on financial results
MTPC will disclose it accordingly if there is any impact on business results.

Contact:
Mitsubishi Chemical Group Corporation
Corporate Communications Division
Osaka Corporate Communications Department+81-6-6205-5119

2/2